WO2008068507A3 - Composés chimiques 576 - Google Patents

Composés chimiques 576 Download PDF

Info

Publication number
WO2008068507A3
WO2008068507A3 PCT/GB2007/004697 GB2007004697W WO2008068507A3 WO 2008068507 A3 WO2008068507 A3 WO 2008068507A3 GB 2007004697 W GB2007004697 W GB 2007004697W WO 2008068507 A3 WO2008068507 A3 WO 2008068507A3
Authority
WO
WIPO (PCT)
Prior art keywords
raf
pyrid
phenylamino
protein kinase
kinase inhibitors
Prior art date
Application number
PCT/GB2007/004697
Other languages
English (en)
Other versions
WO2008068507A2 (fr
Inventor
Brian Aquila
Donald James Cook
Craig Johnstone
Stephen Lee
Paul Lyne
David Alan Rudge
Melissa Vasbinder
Haixia Wang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Brian Aquila
Donald James Cook
Craig Johnstone
Stephen Lee
Paul Lyne
David Alan Rudge
Melissa Vasbinder
Haixia Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008068507(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Brian Aquila, Donald James Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang filed Critical Astrazeneca Ab
Publication of WO2008068507A2 publication Critical patent/WO2008068507A2/fr
Publication of WO2008068507A3 publication Critical patent/WO2008068507A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

L'invention concerne des composés chimiques de formule (I) : ou des sels acceptables du point de vue pharmaceutique de ceux-ci, lesquels possèdent une activité d'inhibition du B-Raf et sont par conséquent utiles pour leur activité anticancéreuse et donc dans des procédés de traitement du corps de l'homme ou de l'animal. L'invention concerne également des procédés pour la fabrication desdits composés chimiques, des compositions pharmaceutiques contenant ceux-ci et l'utilisation de ceux-ci dans la fabrication de médicaments utiles pour produire un effet anticancéreux chez un animal à sang chaud et chez l'homme.
PCT/GB2007/004697 2006-12-08 2007-12-07 Composés chimiques 576 WO2008068507A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86924106P 2006-12-08 2006-12-08
US60/869,241 2006-12-08
US98573207P 2007-11-06 2007-11-06
US60/985,732 2007-11-06

Publications (2)

Publication Number Publication Date
WO2008068507A2 WO2008068507A2 (fr) 2008-06-12
WO2008068507A3 true WO2008068507A3 (fr) 2008-07-31

Family

ID=39386079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004697 WO2008068507A2 (fr) 2006-12-08 2007-12-07 Composés chimiques 576

Country Status (5)

Country Link
AR (1) AR064208A1 (fr)
CL (1) CL2007003557A1 (fr)
PE (1) PE20081351A1 (fr)
TW (1) TW200829566A (fr)
WO (1) WO2008068507A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CN101652352A (zh) * 2006-12-22 2010-02-17 诺瓦提斯公司 用于抑制pdk1的喹唑啉类
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EA019048B1 (ru) 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
PE20120110A1 (es) 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US10554578B2 (en) 2015-06-30 2020-02-04 British Telecommunications Public Limited Company Quality of service management in a network
EP3507382B1 (fr) 2016-09-02 2021-06-23 New England Biolabs, Inc. Analyse de la chromatine au moyen d'une enzyme de coupure
CN111170986A (zh) * 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2023138412A1 (fr) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Composés de pyrimidin-2-amine fusionnés utilisés en tant qu'inhibiteurs de cdk20

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037285A1 (fr) * 2003-10-16 2005-04-28 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
WO2006039718A2 (fr) * 2004-10-01 2006-04-13 Amgen Inc Composes bicycliques azotes d'aryle et leurs procedes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037285A1 (fr) * 2003-10-16 2005-04-28 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
WO2006039718A2 (fr) * 2004-10-01 2006-04-13 Amgen Inc Composes bicycliques azotes d'aryle et leurs procedes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIMAURO, ERIN ET AL: "Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity", J.MED.CHEM, vol. 49, no. 19, 2006, pages 5671 - 5686, XP002480947 *

Also Published As

Publication number Publication date
AR064208A1 (es) 2009-03-18
CL2007003557A1 (es) 2008-08-01
TW200829566A (en) 2008-07-16
WO2008068507A2 (fr) 2008-06-12
PE20081351A1 (es) 2008-11-26

Similar Documents

Publication Publication Date Title
WO2008068507A3 (fr) Composés chimiques 576
WO2007113558A3 (fr) Composés chimiques
WO2006067445A3 (fr) Composes chimiques
MX2007008924A (es) Compuestos quimicos.
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
WO2007071963A3 (fr) Composes chimiques
TW200621259A (en) Chemical compounds
TW200621730A (en) Chemical compounds
TW200736234A (en) Chemical compounds
MX2009004908A (es) Compuestos quimicos.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2008145688A3 (fr) Nouveaux composés
WO2009007749A3 (fr) Composés 947
WO2009098715A3 (fr) Nouveaux dérivés de pyrazolo [3, 4 -d] pyrimidine en tant qu’agents anticancéreux
WO2009007748A3 (fr) Composés 945
WO2009007751A3 (fr) Composé - 946
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
TW200621762A (en) Novel compounds
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2010021918A8 (fr) Composés en tant qu'inhibiteurs de kinases
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824807

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07824807

Country of ref document: EP

Kind code of ref document: A2